贝伐单抗联合5-氟尿嘧啶对人喉癌细胞系Hep-2作用研究

Effect of bevacizumab in combination with 5-fluorouracil on human laryngeal cancer Hep-2 cells in vitro

目的:探讨贝伐单抗(bevacizumab)联合5-氟尿嘧啶(5-FU)对人喉癌细胞系Hep-2的作用。方法:用MTT法检测贝伐单抗、5-FU单药及其联合对人喉癌细胞系Hep-2的增殖抑制,同时采用流式细胞仪检测细胞周期及凋亡情况。结果:贝伐单抗单药及5-FU单药对人喉癌细胞系Hep-2均有明显抑制作用,两药联合具有显著协同作用(P<0.05)。贝伐单抗主要使细胞阻滞于G0/G1期,5-FU则使细胞阻滞于S期。两药联合治疗同时产生G0/G1及S期阻滞。联合组凋亡率显著高于任一单药组(P<0.05),差异有统计学意义。结论:贝伐单抗和5-FU对人喉癌细胞系Hep-2能产生增殖抑制及促凋亡作用,两药联合表现为协同或相加作用。

Objective： To investigate the effect of bevacizumab combined with 5-FU on human laryngeal cancer cell line Hep-2. Methods： The inhibitory effect of bevacizumab, 5-FU, and their combination on proliferation of Hep-2 cell in vitro was assessed by MTT assay. The cell cycle and cell apoptosis were detected by flow cytometry. Results： Both bevacizumab and 5-FU significantly inhibited the proliferation of Hep-2 cells, and showed a synergistic effect in combined use （P〈0.05）. Bevacizumab and 5-FU caused cell cycle arrest at G0/GI phase and S phase, respectively. Combined use of the two drugs resulted in significant reduction of the Ga-phase cell percentage, and the cell cycle arrest at both G0/G1 phase and S phase. The co-administration of the two drugs also significantly increased the apoptosis rate of the cells （P〈0.05）. Conclusion： Bevacizumab and 5-FU show a synergistic effect in inhibiting the proliferation and inducing the apoptosis of Hep-2 cells.